Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP2138 + ramucirumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (ramucirumab, Paclitaxel, ASP2138), Subcutaneous (ASP2138, In Some Trial Arms)
01
Overview
**ASP2138 + ramucirumab + paclitaxel** is an investigational combination therapy being studied for the treatment of advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma with Claudin 18.2 (CLDN18.2) expression. - **ASP2138** is a bispecific monoclonal antibody designed to bind CLDN18.2 on tumor cells and CD3 on T-cells, engaging the immune system to attack cancer cells expressing CLDN18.2. - **Ramucirumab** is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis (blood vessel formation). - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules, disrupting cell division and inducing apoptosis. This specific combination is being evaluated as second-line treatment for patients with metastatic or locally advanced unresectable gastric or GEJ adenocarcinoma, particularly after progression following first-line platinum and fluoropyrimidine chemotherapy. Ramucirumab plus paclitaxel is standard in this setting, with ASP2138 added for immune engagement[1][4][7].
- Other names
- CyramzaTaxol
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CD3 (T-cell surface glycoprotein CD3)TUBB (Tubulin (alpha and beta subunits))Claudin 18.2
Beyond the preview
Go deeper on ASP2138 + ramucirumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP2138 + ramucirumab + paclitaxel.